https://aprepitantantagonist.c....om/metastatic-basal-
Up to 55% of non-APL severe myeloid leukemias (AML) shortage a molecular target ideal for standard disease monitoring. We aimed to gauge the prognostic importance of WT1 gene expression at early stages of intensive treatment. ABL and who achieved remission after one to two cycles of induction therapy were analyzed. WT1 expression had been assessed in peripheral blood making use of a standardized European LeukemiaNet strategy. Overexpression was defined as 50 copies/10 I
Like
Comment
Share
